Loading the company profile
Public data, as of October 2026
Company profile
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited reported about 260,000 tCO₂e for 2024, and 67% of it sits in Scope 3, in the value chain beyond the company's own operations.
SBTi statusValidated Targets
Near-term status: Validated Targets. Net-zero status: no net-zero target on record.
Where insetting fits
Scope 3 is 67% of the footprint, the part of the value chain that supplier emissions reductions can reach.
Peer position
Scope 3 is 67% of the footprint, below the peer median of 91%.
Voluntary retirements
No voluntary retirement names this company as beneficiary yet.
Emissions
How the reported footprint breaks down by scope and year.
tCO₂e, GHG Protocol scopes
Source: published disclosure, FY2024
Peer benchmark
How Glenmark Pharmaceuticals Limited compares with its industry peers on Scope 3.
Peers: companies in the SBTi industry "Pharmaceuticals, Biotechnology and Life Sciences", by Scope 3 share of the latest reported footprint.
CompanyScope 3 share%
- Glenmark Pharmaceuticals LimitedThis company67%
- McKesson Corporation99%
Company profile
A claimed profile keeps the figures accurate and shows the company’s projects.
Claiming is free. Your team can correct data, add newer disclosures and list reduction projects from your value chain, so that customers and suppliers can co-fund them.
- 1Confirm employment at the company